English
Back
Download
Log in to access Online Inquiry
Back to the Top

Moderna loses patent fight against Arbutus related to vaccines; Arbutus up 40%

A federal appeals court has upheld a ruling by the U.S. Patent and Trademark Office to not invalidate patents held by $Arbutus Biopharma (ABUS.US)$, dealing a blow to $Moderna (MRNA.US)$.
The court ruled that Moderna had no standing to appeal.
The patents in question cover a novel lipid formulation for nucleic acid delivery. These lipid nanoparticles are essential to protect mRNA therapies as they travel through the body to cells.
As a result, Arbutus may be eligible for royalties from Moderna from sales of its COVID-19 vaccine.
Moderna had argued that the claims in the patents were obvious and upholding them would open the company to patent infringement lawsuits.
Moderna loses patent fight against Arbutus related to vaccines; Arbutus up 40%
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
1
21
+0
13
Translate
Report
75K Views
Comment
Sign in to post a comment

View more comments...

495
Followers
80
Following
634
Visitors
Follow
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.